Health Benefits 101: Pharmacogenomics (PGx)

Pharmacogenomics – commonly abbreviated PGx – is no longer a niche topic reserved for geneticists and academic researchers. For payers, self-funded employers, and benefit managers, PGx has become a strategy worth understanding and acting on. This is especially true as plan sponsors tackle rising healthcare costs, “trial and error” prescribing inefficiencies, and the mounting pressure to demonstrate positive outcomes.

But even though PGx has become a more common term within healthcare, there are still questions surrounding it: what it means, why the clinical and coverage landscape has shifted, what the barriers to adoption have been, how they’re being addressed, and how Capital Rx’s Rx Helix program – powered by our enterprise health platform (EHP) Judi® - is delivering measurable precision medicine results at a fraction of the cost.

What is PGx?

At its core, PGx examines genetic variants that impact the body’s ability to process a medication – the medication-specific gene markers captured in both the FDA Table of Pharmacogenomic Biomarkers and in FDA drug labels – to determine how a patient will break down, respond to, or experience adverse effects from a given medication. The goal is to enable precision medicine: healthcare decisions tailored to each patient’s genetic blueprint.

In other words, as it was explained during an episode of the Astonishing Healthcare podcast, “Pharmacogenomics is ensuring that the medications you take match well with the genes you have in your body that you've inherited from your parents.”

Why PGx Matters

One of the clearest cases for PGx testing is in psychiatry. Depression treatment today still relies heavily on “trial and error” prescribing. That could mean multiple, sequential medication trials, each lasting around four to six weeks, with no guarantee of success. The STAR*D study found that fewer than 40% of patients achieve remission after their first treatment trial, and only 67% reach remission after up to four trials. Each failed trial increases the probability of an adverse event, prolonged suffering, and added costs.

PGx genes like CYP2D6 and CYP2C19 are among the most clinically significant with respect to mental health medications. Variations in these genes impact how patients metabolize commonly prescribed antidepressants such as SSRIs and SNRIs. A patient who is a poor metabolizer may have a higher risk of experiencing toxicity with a standard dose; while an ultrarapid metabolizer may experience no therapeutic effect at all. PGx helps to identify these PGx profiles thus enabling care teams to select the right drug and the right dose to result in faster symptom management, fewer adverse events, and lower total cost of care.

Oncology is another therapeutic area where PGx makes an impact, with over 100 drugs carrying pharmacogenomic labeling information as of 2022. The count has continued to grow since then.  

Companion diagnostics in this space can often mean life-or-death: TPMT variants determine safe dosing of azathioprine; DYPD variants affect 5-FU toxicity risk; EGFR mutations guide targeted lung cancer therapy.

Other specialties with meaningful PGx applications include neurology and infectious disease. The HLA-B*5701 variant identifies patients at high risk of severe hypersensitivity to abacavir, an HIV medication – and testing before prescribing is now standard of care.

The throughline across all these specialties (and those not mentioned) is this: PGx transforms prescribing from a “trial and error” approach to a personalized one tailored to treatment success.

Traditional Barriers to Adoption

Despite compelling clinical evidence, PGx adoption has faced real friction. Understanding those barriers is essential context for any benefits decision-maker evaluating a PGx testing program.

Cost and Billing Friction

PGx testing cost varies dramatically depending on how it’s administered. When PGx is ordered through the medical benefit, costs can exceed $5,000, largely driven by physician ordering fees, multiple vendor touchpoints, and duplicative testing. Administered through a clinical program like Rx Helix as part of the pharmacy benefit, the same PGx test can cost significantly less, as the PBM model streamlines the process (one multigene panel test, pharmacist-led results interpretation, and direct integration into the clinical workflow), offering PGx testing at a fraction of the cost compared to the medical billing alternative.

Lack of Actionable Clinical Guidelines

Historically, prescribers had limited guidance to act on. That gap has narrowed significantly, though. CPIC guidelines provide practitioners with actionable recommendations for high-evidence (Level A, B, A/B) gene-drug interaction pairs. These CPIC guidelines give clinicians a clear, defensible foundation to drive PGx-informed prescribing decisions and have been a key driver of broader adoption.

Reimbursement Uncertainty

CMS coverage for PGx testing received a major boost with Local Coverage Determination (LCD) L39073. This establishes that PGx testing is medically appropriate when supported by high levels of evidence. The determination also clarifies that PGx testing is not like routine lab tests such as HbA1c or a lipid panel, it’s really a “one and done” test that patients can benefit from throughout their care journey with little to no need for re-testing. After all, DNA doesn’t change. This eliminates concerns about duplicative testing and ongoing cost.

Data Siloes and Integration Challenges

Traditional benefit administration splits medical claims, pharmacy claims, eligibility, and payments across multiple vendors. As a result, there is no real-time visibility, delayed insights, and no mechanism to flag PGx candidates during routine drug utilization review (DUR). Without unified medical and pharmacy claims infrastructure – like what Judi Health provides – even the best PGx program operates in a vacuum.

Clinical Pharmacist Expertise

Not all PGx programs are delivered equally. Effective implementation requires clinical pharmacist PGx decision support: pharmacists trained to combine test results with deep pharmacology knowledge – drug-drug interactions, dosing nuances, formulary context – to deliver recommendations that are both clinically sound and actionable within the member’s specific benefit structure.

Rx Helix: Precision Medicine in Practice

Capital Rx’s PGx program, Rx Helix, is built for clinical rigor and operational efficiency, and it’s producing measurable results.

In short, Rx Helix uses an at-home panel test covering 25+ high-evidence genes that inform prescribing for over 100 medications. Genes are selected based on CPIC guidelines, PGx evidence, and FDA labeling. The panel spans psychiatry, cardiology, pain management, oncology supportive care, and more.

So how does this program work?  

Judi flags a plan member who may benefit from PGx testing during existing DUR processes. When a member is prescribed a target medication with a known gene-drug interaction – an antidepressant, anticoagulant, an opioid, etc. - the system automatically triggers a PGx test offer. Enrollment is seamless: the member signs up to receive a kit at home, completes a buccal swab, and returns it via prepaid mail.

When the results are in, a PGx-trained clinical pharmacist on the team contacts the member directly. Leveraging vendor-supported decision support tools, the pharmacist interprets the results in the context of the member’s current medications, medical history, and specific benefit plan structure. They then offer medication recommendations based on evidence and aligned with the formulary. When changes are warranted- whether discontinuation, therapy substitution, or dose adjustment- the pharmacist collaborates with the prescriber to implement them, reducing friction for both member and provider.

Rx Helix reduces trial and failure prescribing cycles, avoids wasteful spend on "trial and error" prescribing, and keeps PGx testing costs low.

‍

‍

How Rx Helix Works

A  member was identified in real-time by Judi as eligible for Rx Helix after a recent fill of omeprazole, a medication known to have potential drug-gene interactions. The member’s pharmacogenomic (PGx) test showed the member could not process the medication efficiently, increasing the risk of side effects such as gastrointestinal issues, bone fractures, low vitamin levels, and serious infections like C. difficile. The member was educated on the risks associated with prolonged use, and the prescriber was contacted to recommend discontinuing or adjusting the therapy. The prescriber agreed with the recommendation, and the medication has not been refilled. The member expressed sincere appreciation for the personalized care received. This timely, pharmacist‑led intervention may have prevented a serious adverse event, demonstrating the impact of real‑time data and individualized pharmacogenomic care.

‍

How Unified Claims Processing™ Enhances and Expands PGx Testing

The clinical case for PGx is well established. What has made it difficult to operationalize at scale is electronic infrastructure.

In a traditional approach, everything is siloed: medical claims are processed by one vendor, pharmacy by another, and that duplicated effort results in higher costs and more errors. As our Founder & CEO, AJ Loiacono, explained, “If you do something twice, at best, it's twice as expensive.”

Judi Health solves this by unifying pharmacy and medical claims processing (along with vision and dental) on a single cloud-native platform: Judi. That means everything – eligibility, plan design, DUR, payments, and analytics – lives on a single system. That consolidated view also strengthens care coordination between Capital Rx’s clinical team and prescribing providers, ensuring PGx insights translate into action at the point of care.

Critically, a unified workflow enables a shift from a reactive to a proactive PGx identification model. In a traditional model, members become eligible for testing only after filling a prescription. With Judi, members can be identified and tested based on specific diagnoses and conditions before therapy is initiated, optimizing treatment earlier in the care journey, when the clinical and financial impact is the greatest.

• Real-Time PGx Flagging: Judi identifies members with claims for medications involving known gene-drug interactions and triggers the Rx Helix enrollment workflow automatically.
  

• Pharmacist Workflow Integration: PGx results are seamlessly integrated into decision-support software, allowing PGx-trained pharmacists to provide formulary-based recommendations within the member’s actual benefit structure. This eliminates the need for manual data reconciliation.

• Total Cost of Care Analytics: With a unified look at the data, it’s easier to measure PGx ROI across medical and pharmacy spend – reduced ER visits, fewer drug switches, lower total pharmacy spend, and more.

The Future of Health Benefit Administration

While traditionally PGx has bumped into a variety of barriers that prevented wider adoption – ranging from testing costs, CMS coverage uncertainty, data fragmentation, and lack of CPIC guidelines – many of these challenges have been substantially addressed, especially when leveraging modern enterprise health technology, like Judi. What remains now is execution.

Our Clinical team recently presented a poster at the Pharmacy Quality Alliance (PQA) annual meeting, diving deeper into Rx Helix and results from the program. Click here to check it out!

Ready to bring precision medicine to your organization? Contact our team today to learn how Rx Helix and Judi Health can reduce costs while improving health outcomes.

‍